EXPLORE!

FDA Grants Accelerated Approval to Vanrafia for Proteinuria Reduction

  428 Views

Emedinexus    07 April 2025

Vanrafia received accelerated FDA approval based on a pre-specified interim analysis from the Phase III ALIGN study, demonstrating a reduction in proteinuria at 36 weeks compared to placebo.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.